.png)
2023 ACCP Annual Meeting Invited Keynote
Cynthia J. (CJ) Musante, PhD, Vice President, Scientific Research & Global Head of Quantitative Systems Pharmacology, Pfizer Worldwide Research, Development & Medical Clinical Pharmacology & Bioanalytics
Presentation Title: Benefit vs Risk: What’s the Optimal Dose of Artificial Intelligence in Clinical Pharmacology?
ACCP is pleased to announce that its 2023 Invited Keynote is Cynthia J. (CJ) Musante, PhD, Vice President of Scientific Research and the Global Head of Quantitative Systems Pharmacology (QSP), Clinical Pharmacology & Bioanalytics, at Pfizer Inc. Dr. Musante received her PhD in Applied Mathematics from North Carolina State Univ and has over twenty years of experience in QSP modeling. At Pfizer, her group is responsible for developing and applying systems models and disease platforms across the portfolio to enhance the robustness and quality of decision making at the program and therapeutic-strategy level. Dr. Musante is an advocate for model-informed drug development, both internally and externally. She is a frequent organizer and invited speaker at national and international conferences and currently serves as President of the Int’l Society of Pharmacometrics.
Dr. Musante will present 'Benefit vs Risk: What's the Optimal Dose of Artificial Intelligence in Clinical Pharmacology?" on Monday, September 11, 2023 at 10:00 AM PT. Artificial intelligence (AI) is revolutionizing various domains of healthcare and its potential in clinical pharmacology is both promising and challenging. The integration of AI and machine learning (AI/ML) in pharmacological research and clinical practice has the potential to enhance data-driven decision making, accelerate drug discovery and development and improve patient outcomes through personalized medicine approaches. However, determining the optimal integration or “dose” of AI/ML in clinical pharmacology requires careful consideration of the benefits it brings, along with its associated risks and ethical considerations. The current landscape and future potential of AI/ML applications will be examined, ranging from drug discovery and development to individualized dosing and adverse event prediction. While AI offers unprecedented opportunities, it is important to acknowledge and address the risks and challenges associated with its implementation. Ethical considerations, data availability, quality & privacy and algorithmic biases are among the critical factors that demand careful attention. This talk will highlight the need for transparency, robust validation and explainability in AI-driven systems to ensure trust, reliability and accountability in clinical decision-making processes. Striking the right balance between human expertise and AI-driven recommendations becomes paramount, as clinical pharmacologists navigate the complexities of incorporating AI/ML into their research and practice. By weighing the potential benefits against the inherent dangers, this talk aims to provide attendees with practical insights to inform the safe and effective use of AI/ML, fostering a future where AI-powered clinical pharmacology maximizes outcomes while minimizing risks.
Jack A. Yanovski, MD, PhD, Senior Investigator, Section on Growth and Obesity, National Institute of Health (NIH), will present on his body of work in the field of pediatric obesity.
Jack A. Yanovski, MD, PhD, is Chief of the Section on Growth and Obesity in the Division of Intramural Research. Dr. Yanovski obtained his medical degree in 1986 at the University of Pennsylvania, where he was also awarded a PhD in Physiological Psychology in 1989. After residency training in Pediatrics at the Children’s Hospital of Philadelphia, Dr. Yanovski completed a fellowship in Pediatric Endocrinology at the NIH, conducting clinical and basic research with Dr. Gordon Cutler in the Developmental Endocrinology Branch, where he developed the dexamethasone-suppressed ovine corticotropin-releasing hormone test for the differential diagnosis of hypercortisolism. This test has become part of the standard armamentarium of tests used by endocrinologists. Dr. Yanovski remained at the NIH to serve as Chief of Pediatrics for the Warren Grant Magnuson Clinical Center from 1994-1998. In response to the growing problem of pediatric obesity, Dr. Yanovski returned to NICHD to create the Unit on Growth and Obesity in the NICHD’s Developmental Endocrinology Branch and serve as its Head. Dr. Yanovski has carried out a series of clinical studies related to the evaluation and treatment of overweight and obesity in children and adults, as well as laboratory investigations of the molecular etiologies of obesity. His randomized controlled trials have elucidated the limitations of current pharmacotherapeutic approaches for treatment of pediatric obesity and his observational studies have demonstrated the importance of disinhibited eating behaviors for pediatric obesity. His lab has also elucidated the roles of the melanocortin 3 receptor and brain-derived neurotrophic factor in human body weight regulation. Dr. Yanovski has authored or co-authored over 350 manuscripts and has served as a regular reviewer for the New England Journal of Medicine, Lancet, JAMA, and many other journals. He has served as a standing member of the NSCF, NIH Study Section, as a consultant for FDA advisory panels, and on the editorial boards of several obesity, pediatric, and endocrine journals. Dr. Yanovski has also served as Chair of The Obesity Society’s annual Scientific Meeting. Among other awards, he has received the Public Health Service’s Outstanding Service Medal for innovative studies on obesity, the NIH Director’s Ruth L. Kirschstein Mentoring Award, and both the Thomas A. Wadden Award for Distinguished Mentorship and the Bar-Or Award for Excellence in Pediatric Obesity Research from The Obesity Society.